-
Consumables in the eight regions of Henan have been bargained to start mass production
Time of Update: 2021-04-27
Medical Network News on March 25 Bargaining prices for supplies in eight regions On March 24, according to the news from Huazhao Equipment Network, the Xinxiang City Drugs and Medical Consumables Alliance Centralized Procurement Platform issued the "Notice on Online Quotations for the Centralized Procurement of Medical Consumables Alliance of Eight Cities (Counties) including Xinxiang City, Henan Province".
-
How should traditional Chinese medicine companies spin off traditional Chinese medicines and transform them?
Time of Update: 2021-04-27
On March 22, Livzon Pharmaceutical announced that it plans to acquire 40% of Tianjin Tongrentang held by Tasly Holding Group as a financial investor for 724 million yuan.
-
FDA concerns about the safety of Pfizer/Lilly's new painkiller tanezumab
Time of Update: 2021-04-27
”The US FDA added, “Although the two companies have proposed clinical risk mitigation strategies in the study, the risk of RPOA is still worrying, because a considerable number of patients with adverse events require total joint replacement.
-
China's first RET inhibitor, Cornerstone Pharmaceuticals, pratinib approved
Time of Update: 2021-04-27
CStone Pharmaceuticals announced today that NMPA has approved the marketing application of pratinib capsules for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has previously received platinum-containing chemotherapy for transfection rearrangement (RET) gene fusion-positive non-small cell lung cancer (NSCLC) Treatment of adult patients.
-
The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States
Time of Update: 2021-04-27
Recently, the company announced that its targeted anticancer drug Pepaxto (melphalan flufenamide, also known as melflufen) has been included in the National Cancer Comprehensive Network (NCCN) clinical practice for multiple myeloma guide.
-
Huahai Pharmaceutical Sitagliptin Phosphate Tablets Received Acceptance from CDE
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseAt present, the only companies approved for sitagliptin phosphate tablets in the domestic market are Merck and Dongyang Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group.
Sitagliptin phosphate tablets from 11 companies are under review and approval.
-
Boehringer Ingelheim's new drug BI 425809 for schizophrenia received clinical approval
Time of Update: 2021-04-27
The primary end point was the change from baseline in the patient's overall MCCB overall T-score (consensus version of the schizophrenia cognitive function test suite, a neurocognitive efficacy assessment test for schizophrenia) at the 12th week.
-
Eli Lilly’s business model adjustment for multinational pharmaceutical companies has a large number of drugs "patent cliff" here?
Time of Update: 2021-04-27
The CCO mixed line team is cancelled, what will happen to the patent expired drugs?In addition, in the email, Eli Lilly also stated, “During the business transformation and adjustment at the end of last year, based on the uncertain factors of the three products (Xinbaida, Cialy, and Futai), in order to smooth the business transition and explore uncertainties.
-
The Liaoning Provincial Food and Drug Administration issued a public solicitation of opinions on the preparation of four Chinese herbal medicines including yew
Time of Update: 2021-04-27
On March 24, the Liaoning Provincial Food and Drug Administration issued an announcement on publicly soliciting opinions on the processing standards of four Chinese herbal medicines including yew.
-
Zhejiang's drug access "opens the gate", opportunities for many large varieties are coming
Time of Update: 2021-04-27
List of certain commercial insurance: Medical Network News, March 25, Zhejiang Province has been relatively tight on product access cards since the 2014 standard.
List of certain commercial insurance: Medical Network News, March 25, Zhejiang Province has been relatively tight on product access cards since the 2014 standard.
-
Yiling Pharmaceutical Dextromethorphan Hydrobromide Tablets Passed the Consistency Evaluation
Time of Update: 2021-04-27
On March 24, Yiling Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for dextromethorphan hydrobromide tablets approved and issued by the National Medical Products Administration.
At present, only 2 dextromethorphan hydrobromide tablets in China have passed the consistency evaluation (including the products approved by the company this time).
-
Tide Pharmaceuticals won the title of "Model of Capital Civilized Unit"
Time of Update: 2021-04-27
The picture above shows the list of pacesetters of civilized units in the capital of the Economic Development ZoneThe capital's spiritual civilization creation activity is held every three years and is an important honor in the field of the capital's spiritual civilization construction.
-
A complete analysis of the development of Shanghai's hospital drug market in 2020
Time of Update: 2021-04-27
Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020 Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
-
Hutchison Pharma enters into an agreement to sell non-core non-prescription drug joint ventures for US$169 million
Time of Update: 2021-04-27
On March 24, Hutchison Medicine announced that it had reached a US$169 million transaction agreement with GL Mountrose Investment Two Limited, which is controlled and managed by Telford Capital.
100% equity of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co.
-
Arikayce approved in Japan: the first drug to treat nontuberculous mycobacterial lung disease caused by MAC
Time of Update: 2021-04-27
The study was carried out in patients with refractory NTM lung disease caused by MAC, and the results showed that the study reached the primary endpoint: at the 6th month of treatment, compared with a guideline-based multi-drug regimen (MDR), Arikayce once a day Combined treatment with MDR can significantly increase the conversion rate of sputum culture (p<0.
-
Hebei Province: Strengthening the supervision and inspection of medical expenses and prohibiting large prescriptions
Time of Update: 2021-04-27
Standardize the interactive process of doubtful points—strengthen the effect of agreement clauses and indicator constraints, and include priority use of medical insurance catalog drugs (medical consumables), control of the proportion of self-pay, prohibition of inducing drugs to be purchased out of hospitals, and issuing large prescriptions in violation of regulations, etc.
-
Hengrui Medicine's PD-1 monoclonal antibody anti-cancer new drug submits two more marketing applications
Time of Update: 2021-04-27
First-line treatment for squamous non-small cell lung cancerThis is a randomized, double-blind, phase 3 controlled clinical study named SHR-1210-III-307, which aims to evaluate carrelizumab for injection or placebo combined with paclitaxel and carboplatin for advanced or metastatic The effectiveness and safety of first-line treatment of squamous NSCLC.
-
A pharmaceutical company fined 10,000 yuan for producing and selling unqualified pharmaceutical packaging materials
Time of Update: 2021-04-27
The content and basis of administrative punishment:According to the provisions of Article 64 Paragraph 2 of the "Administrative Measures for Packaging Materials and Containers in Direct Contact with Drugs", supervise and process 669,630 sets of oral liquid medicinal high-density polyethylene bottles (batch number: 19081301) produced by your company, and provide you with The company imposed a fine of 10,000 yuan.
-
Accelerated hospital admission after medical insurance? The top three soared 41 new blockbuster drugs such as Hengrui and Baekje PD-1!
Time of Update: 2021-04-27
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
-
Guizhou Bailing: Ruikang Hospital received approval for registration of preparations from medical institutions
Time of Update: 2021-04-27
On March 25, Guizhou Bailing announced that the company signed a "Technology Development (Cooperation) Contract" with Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine
